Andreas is a European and UK Patent Attorney with over 15 years’ of experience. His practice is focussed on supporting the launch of clients’ commercial products. He specialises in biological therapeutics and diagnostics, and in particular therapeutic antibody, gene therapy, and cell therapy products. By nature, the work is commercially sensitive and often contentious, and Andreas has considerable experience in handling innovator-on-innovator oppositions and appeals at the EPO both attacking and defending.
Clients particularly value Andreas’ holistic strategic advice covering filing and prosecution strategies, portfolio management, freedom-to-operate and finance-related due diligence activities, supplementary protection certificates (SPCs), as well as coordinating with litigators in cases with anticipated or pending parallel EPO and national court proceedings.
Recent work included developing a strategy to navigate the FTO landscape for a projected blockbuster orphan drug product in Europe and the US involving filing of a dozen interrelated EPO oppositions against two leading global pharmaceutical companies which ultimately led to a successful settlement agreement between the parties. Andreas was also involved in the successful EPO opposition defences of Stanford University’s ‘Quake’ patent estate covering commercial non-invasive pre-natal testing (NIPT) methods, which were also litigated in the UK High Court (Illumina, Inc v Premaitha Health Plc).
Andreas’ PhD research focussed on elucidating the regulation of methane and multi-carbon metabolism in the facultative methane-oxidizing bacterium Methylocella silvestris BL2. His research resulted in his authoring several scientific publications and culminated in the sequencing of the M. silvestris genome by the US Department of Energy Joint Genome Institute.
Outside of the office, Andreas delights in spending time with his young family and is a keen scuba diver.
Andreas joined J A Kemp in 2023 after 15 years working at two other leading UK patent attorney firms.